75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Statements of Operations
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Statements of Comprehensive Loss
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Statements of Stockholders' Equity (Deficit)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Statements of Stockholders' Equity (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Statement - Statements of Cash Flows (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance
link:presentationLink
link:calculationLink
link:definitionLink
995467 - Disclosure - Organization and Principal Activities
link:presentationLink
link:calculationLink
link:definitionLink
995477 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995487 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995497 - Disclosure - Cash Equivalents and Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995507 - Disclosure - Collaboration and License Agreements and Supply Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995517 - Disclosure - Property and Equipment, Net
link:presentationLink
link:calculationLink
link:definitionLink
995527 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995537 - Disclosure - Accrued Expenses and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995547 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995557 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995567 - Disclosure - Restructuring and Related Costs
link:presentationLink
link:calculationLink
link:definitionLink
995577 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995587 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995597 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995607 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995617 - Disclosure - Defined Contribution Plan
link:presentationLink
link:calculationLink
link:definitionLink
995627 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995637 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995647 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995657 - Disclosure - Cash Equivalents and Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995667 - Disclosure - Collaboration and License Agreements and Supply Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995677 - Disclosure - Property and Equipment, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995687 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995697 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995707 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995717 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995727 - Disclosure - Restructuring and Related Costs (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995737 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995747 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995757 - Disclosure - Income Taxes (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995767 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995777 - Disclosure - Organization and Principal Activities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995787 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995797 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995807 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995817 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995827 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995837 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995847 - Disclosure - Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995857 - Disclosure - Collaboration and License Agreements and Supply Agreements - Performance Obligations - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995867 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995877 - Disclosure - Collaboration and License Agreements and Supply Agreements - Summary of Deferred Revenue Balance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995887 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995897 - Disclosure - Property and Equipment, Net - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995907 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995917 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995927 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995937 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995947 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995957 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995967 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995977 - Disclosure - Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995987 - Disclosure - Segment Reporting - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995997 - Disclosure - Segment Reporting - Summary of Segment Net Loss Including Significant Segment Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996007 - Disclosure - Restructuring and Related Costs - Summary of Total Restructuring, and Related Costs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996017 - Disclosure - Restructuring and Related Costs - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996027 - Disclosure - Restructuring and Related Costs - Summary of Severance and Other Termination Benefit Expense and Reconciliation of Such Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996037 - Disclosure - Stockholders' Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996047 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996057 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996067 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Option Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996077 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Employee Stock Options Valuation (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996087 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of Status and Activity of Non-vested RSUs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996097 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Fair Value of ESPP Shares Using Option Pricing Model (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996107 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996117 - Disclosure - Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation - Summary of the Status of Call Options (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996127 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Tax Provision (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996137 - Disclosure - Income Taxes - Schedule of Current Provision for Income Taxes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996147 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996157 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Provision (Benefit) for Income Taxes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996167 - Disclosure - Income Taxes - Schedule of Effective Tax Rate of Provision (Benefit) for Income Taxes (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996177 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996187 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996197 - Disclosure - Net Loss Per Share - Summary of Computation of Company's Basic and Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996207 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996217 - Disclosure - Defined Contribution Plan - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Released
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Segments [Domain]
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Foreign
Liability balance
Restructuring Reserve
Restructuring Reserve, Total
Liability balance
Transaction price
Transaction Price
Transaction price.
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred Stock, Shares Issued, Total
Statement of Financial Position Location, Balance [Domain]
Increase (Decrease) in Accounts Payable, Total
Accounts payable
Increase (Decrease) in Accounts Payable
Debt-non-current
Debt, non-current portion
Debt, non-current
Long-Term Debt, Excluding Current Maturities
Plan Name
Plan Name [Axis]
Deferred royalty obligation related to the sale of future royalties.
Deferred Royalty Obligation related to the Sale of Future Royalties [Text Block]
Deferred Royalty Obligation related to the Sale of Future Royalties
Entity Current Reporting Status
Entity Current Reporting Status
US Government Agencies Debt Securities [Member]
U.S. Agency Securities
Operating expenses
Operating Expenses [Abstract]
Level 2
Fair Value, Inputs, Level 2 [Member]
Deferred Tax Assets, Net of Valuation Allowance
Gross deferred tax assets
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, shares authorized
Common Stock, Shares Authorized
Investments in Equity Securities
Investment, Policy [Policy Text Block]
Product and Service
Product and Service [Axis]
Income tax charge related to contingent payment.
Income Tax Charge Related To Contingent Payment
Income tax charge related to contingent payment
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Shell Company
Entity Shell Company
Temporary Equity Balance, Shares
Temporary Equity Balance, Shares
Temporary Equity, Shares Outstanding
Cash and cash equivalents
Cash and Cash Equivalent
Less amounts classified as cash equivalents, Amortized Cost Basis
Operating Lease, Impairment Loss
Impairment charges and related costs
Furniture and Office Equipment
Furniture And Office Equipment [Member]
Furniture and office equipment.
Non-cash interest expense related to the sale of future royalties.
Non-cash Interest Expense Related To The Sale Of Future Royalties
Non-cash interest expense related to the sale of future royalties
Non-cash interest expense related to the sale of future royalties
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
2004 Plan, 2018 Plan and 2021 Plan
Two Thousand Four Plan Two Thousand Eighteen Equity Incentive Plan And Two Thousand Twenty One Equity Inducement Plan [Member]
Two thousand four plan two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan.
Common Stock, Shares, Issued, Total
Common stock, shares issued
Common Stock, Shares, Issued
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Asset Class
Asset Class [Domain]
Statement [Table]
Statement [Table]
Restricted cash
Restricted Cash, Noncurrent
Additions for tax positions taken in the current year
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Two thousand fifteen license agreement.
Two Thousand Fifteen License Agreement [Member]
2015 License Member
2015 License Agreement
Weighted-average estimated grant-date fair value of employee stock options granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Cancellation of redeemable convertible preferred warrants
Cancellation Of Redeemable Convertible Preferred Warrants
Cancellation of redeemable convertible preferred warrants.
Statement [Line Items]
Statement [Line Items]
Contingent payment received
Contingent Payment Received
Contingent payment received.
Warrants to Purchase Common Stock
Warrant [Member]
Entity Filer Category
Entity Filer Category
Number of shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Liabilities and Equity
Total Liabilities and Stockholders' Equity (Deficit)
Substantial doubt about going concern, within one year
Substantial Doubt about Going Concern, within One Year [true false]
Payables and Accruals [Abstract]
Increase (Decrease) in Employee Related Liabilities, Total
Accrued compensation
Increase (Decrease) in Employee Related Liabilities
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total
Changes in unrecognized tax benefits
Payments to Acquire Marketable Securities, Total
Purchases of marketable securities
Payments to Acquire Marketable Securities
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Stock options exercisable, Weighted - Average Exercise Price, Exercisable
Restructuring Type [Axis]
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Axis]
Severance and benefits expense
Severance Costs
Net increase in valuation allowance
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Revenue interest percentage.
Revenue Interest Percentage
Revenue interest percentage
Revenue interest percentage
Prepaid Expenses and Other Current Assets [Member]
Prepaid Expenses and Other Current Assets
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Restructuring and Related Costs [Table Text Block]
Total Summary of Restructuring, and Related Costs
Proceeds from debt refinancing
Proceeds from Issuance of Debt
Less amounts classified as cash equivalents, Fair Value
Cash and Cash Equivalents, Fair Value Disclosure
Proceeds from exercise of options for Vaxcyte shares
Proceeds From Exercise Of Options For Vaxcyte Shares
Proceeds from exercise of options for vaxcyte shares.
Deferred Tax Assets, Valuation Allowance
Less: valuation allowance
Deferred Tax Assets, Valuation Allowance, Total
Remeasurement of liability awards
Remeasurement Of Liability Awards
Remeasurement of liability awards
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
U.S. federal statutory tax rate
U.S. federal statutory rate
Cybersecurity Risk Management Third Party Engaged [Flag]
Documents Incorporated by Reference
Documents Incorporated by Reference [Text Block]
Other Noncash Income (Expense), Total
Other
Other Noncash Income (Expense)
Amortization of issuance costs.
Amortization of issuance costs
Amortization of issuance costs
Total
Effective Income Tax Rate Reconciliation, Percent
Stock Options
Proceeds from sale of future royalties
Proceeds From Sale of Future Royalties
Proceeds from the sale of future Vaxcyte royalties
Income Tax Authority
Income Tax Jurisdiction [Axis]
Initial transaction price
Initial transaction price.
Geographical
Geographical [Domain]
Asset-backed Securities
Asset-Backed Securities [Member]
2018 Merck Agreement
Two Thousand Eighteen Merck Agreement [Member]
Two thousand eighteen Merck agreement.
First installment milestone payment received
First installment milestone payment received.
First Installment Milestone Payment Received
Conversion of redeemable convertible preferred stock and warrant to common stock in connection with initial public offering
Temporary Equity Conversion Of Redeemable Convertible Preferred Stock And Warrant To Common Stock Value
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering, value.
BMS Agreement and the 2018 BMS Master Services Agreement
2018 BMS Master Services Agreement
BMS Agreement and the 2018 BMS Master Services Agreement
BMS agreement and two thousand eighteen BMS master services agreement.
Royalty obligation.
Royalty Obligation [Table Text Block]
Schedule of Royalty Obligation transaction
Allowance for doubtful accounts receivable
Accounts receivable, reserve for credit losses
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Accounts Receivable, Allowance for Credit Loss
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in-capital
Additional Paid in Capital, Common Stock
Stock transaction associated with taxes withheld on restricted stock units
Stock transaction associated with taxes withheld on restricted stock units
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Vaxcyte investment
Deferred Tax Liabilities, Investments
Related Party [Member]
Related Party
Remaining Shares Reserved for Issuance under 2018 Equity Incentive Plan and 2021 Equity Inducement Plan
2018 Equity Incentive Plan and 2021 Equity Inducement Plan
Two Thousand Eighteen Equity Incentive Plan And Two Thousand Twenty One Equity Inducement Plan Member
Two thousand eighteen equity incentive plan and two thousand twenty one equity inducement plan.
Defined Contribution Plan [Text Block]
Defined Contribution Plan
Property Plant And Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Sales of marketable securities
Proceeds From Sales Of Marketable Securities
Proceeds from sales of marketable securities.
Total options granted
Share-based compensation arrangement by share-based payment award options, shares granted
Granted, Shares
Cybersecurity Risk Management, Strategy, and Governance [Table]
Summary of Computation of Company's Basic and Diluted Net Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Equity Securities
Equity Securities [Member]
Property, Plant and Equipment, Net [Abstract]
Preclinical research and clinical development expenses
Preclinical research and clinical development expenses.
Preclinical research and clinical development expenses
Preclinical research and clinical development expenses
Contingent payment recognized as deferred revenue
Contingent payment recognized as deferred revenue.
Contingent Payment Recognized As Deferred Revenue
Investment, Name [Axis]
Net loss per share, basic
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Base rent abatement sublease period
Base Rent Abatement Sublease Period
Base rent abatement sublease period.
Tasly Biopharmaceuticals Co., Ltd. ("Tasly")
Tasly Biopharmaceuticals Co. Ltd [Member]
Tasly Biopharmaceuticals Co. Ltd.
Options vested and outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Stock options outstanding, Ending Balance, Shares
Stock options outstanding, Beginning Balance, Shares
Leasehold impairment charges
Impairment of Leasehold
Total current liabilities
Liabilities, Current
Proceeds from sale of equity securities, net
Proceeds from Sale of Equity Securities, FV-NI
Fair market value
Accounts receivable
Increase (Decrease) in Accounts Receivable
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Federal
Domestic Tax Jurisdiction [Member]
Interest and other income (expense), net
Interest and Other Income (Expense), Net
Interest and other income (expense), net.
Interest and other (income) expense, net
Consolidation Items [Domain]
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Restructuring plan, percentage of workforce reduction
Equity, Attributable to Parent [Abstract]
Stockholders' equity (deficit):
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Stock based compensation
Organization and Principal Activities
Nature of Operations [Text Block]
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Canceled and forfeited, Shares
Proceeds from Issuance Initial Public Offering
Proceeds from sales of common stock, net of issuance costs
Sale of Stock, Price Per Share
Offering price
Foreign
Current Foreign Tax Expense (Benefit)
Series C and E Redeemable Convertible Preferred Stock
Series C And E Redeemable Convertible Preferred Stock [Member]
Series c and e redeemable convertible preferred stock.
Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders equity.
Stockholders Equity [Table]
Stockholders Equity [Table]
Common Stock Options Issued and Outstanding
Common Stock Option Issued And Outstanding [Member]
Common stock option issued and outstanding.
Deferred tax liabilities fixed assets.
Deferred Tax Liabilities Fixed Assets
Fixed asset basis
Maturities of marketable securities
Proceeds From Maturities Of Marketable Securities
Proceeds from maturities of marketable securities.
Lease Contractual Term [Axis]
Lease Contractual Term
Upfront payment received
Upfront Payment Received
Upfront payment received.
Upfront payment received
Contract with Customer, Liability, Total
Deferred revenue
Deferred revenue
Deferred revenue
Contract with Customer, Liability
Amendment Flag
Amendment
Amendment Flag
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Summary of significant accounting policies.
Product and Service
Product and Service [Domain]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Astellas Pharma Inc. ("Astellas")
Astellas Pharma Inc. ("Astellas") [Member]
Astellas pharma inc. ("Astellas").
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
U.S. federal statutory rate
Warrant exercisable date
Class of Warrant or Right, Date from which Warrants or Rights Exercisable
Annual increase period of common stock reserved for issuance
Annual Increment Period Of Common Stock Reserved For Issuance
Annual increase period of common stock reserved for issuance.
Issuance of warrants to purchase shares
Warrant to purchase stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
2020 Merck Master Services Agreement
Two Thousand Twenty Merck Master Services Agreement [Member]
2020 Merck master services agreement.
Basis of Presentation and Summary of Significant Accounting Policies
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Net Loss Per Share
Earnings Per Share, Policy [Policy Text Block]
Liabilities and Equity [Abstract]
Liabilities and Stockholders' Equity (Deficit)
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Change in operating lease liability
Increase (Decrease) in Operating Lease Liability
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock Options Issued and Outstanding
Common Stock
Common Stock [Member]
Cybersecurity Risk Role of Management [Text Block]
General business credits
Tax Credit Carryforward, Amount
Weighted - Average Exercise Price, Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Lessee, Operating Lease, Liability, to be Paid, Year Three
2027
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Less accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Entity Address, Address Line One
Entity Address, Address Line One
Clinical Trials
Clinical Trials [Member]
Clinical trials.
Schedule of Employee Stock Options Valuation
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
2021 Equity Inducement Plan
Two Thousand Twenty One Equity Inducement Plan Member
Two thousand twenty one equity inducement plan.
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Income Taxes
Income Tax, Policy [Policy Text Block]
Temporary Equity Balance
Temporary Equity Balance
Temporary Equity, Carrying Amount, Attributable to Parent
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Supplemental disclosure of cash flow information
Supplemental Cash Flow Information [Abstract]
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency Translation
Astellas License and Collaboration Agreement
Astellas License and Collaboration Agreement [Member]
Astellas license and collaboration agreement.
Statement of Financial Position Location, Balance [Axis]
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Total deferred tax assets
Deferred Tax Assets, Gross
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Net unrealized loss on available-for-sale securities
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Net unrealized income (loss) on available-for-sale securities
Class of Warrant or Right
Class of Warrant or Right [Axis]
Document Type
Document Type
Document Type
Income Taxes Paid, Net, Total
Income Taxes Paid, Net
Income tax paid
Income tax paid
Income taxes paid, net of (refunds)
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Common stock fair value
Equity, Fair Value Disclosure
Equity, Fair Value Disclosure, Total
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]
Other comprehensive income (loss):
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Restructuring Reserve, Current
Restructuring related accrual
Milestone payment received
Milestone Payment Received
Milestone payment received.
Milestone payment receivable.
Milestone Payment Receivable
Milestone payment receivable
Milestone payment receivable
Additional milestone payment received
Additional Milestone Payment Received
Additional milestone payment received.
Issuance costs
Temporary Equity Issuance Costs
Temporary equity issuance costs.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase in cash, cash equivalents and restricted cash
Subsequent Event Type [Domain]
BioNova Option Agreement
BioNova Option Agreement [Member]
BioNova option agreement.
Antidilutive securities excluded from computation of net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Return and retirement of common stocks, shares
Stock Repurchased and Retired During Period, Shares
Computer Equipment and Software
Computer Equipment And Software [Member]
Computer equipment and software member.
Issuance of common stock in connection with private placement
Stock Issued During Period Value With Private Placement
Stock issued during period value with private placement.
Impairment of long-lived assets
Impairment / write-down of long-lived assets and other related costs
Impairment charges
Common stock, par value
Common Stock, Par or Stated Value Per Share
Security deposit
Security Deposit
2019 EMD Serono Supply Agreement
Two Thousand Nineteen E M D Serono Supply Agreements [Member]
2019 EMD Serono supply agreements.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Stock options outstandng, Weighted - Average Remaining Contract Term
Expected volatility, Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Amortized Cost Basis
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, Available-for-sale, Total
Fair Value
Debt Securities, Available-for-Sale
Period for cumulative ownership change
Period For Cumulative Ownership Change
Period for cumulative ownership change.
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]
Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]
Schedule of organization consolidation and presentation of financial statements.
Document Financial Statement Error Correction [Flag]
Exercise of common stock options, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercised, Shares
Exercised, Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance
Options unvested and outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares
Restructuring and Related Cost, Expected Cost
Restructuring and Related Cost, Expected Cost, Total
Restructuring plan, expected amount to be paid
Amount expected to be incurred in connection with severance
Initial Premises
Initial Premises [Member]
Initial premises.
Deferred tax assets fixed assets.
Deferred Tax Assets Fixed Assets
Fixed asset basis
Vaxcyte, Inc.
Vaxcyte Agreement
Vaxcyte, Inc.
Vaxcyte, Inc.
Accrued Liabilities, Current, Total
Accrued compensation
Accrued Liabilities, Current
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Term of warrant exercisable
Class Of Warrant Or Right Term Of Warrant
Class of warrant or right term of warrant.
Ipsen Agreement [Member]
Ipsen agreement.
Ipsen Agreement
California
CALIFORNIA
Blackstone Life Sciences
Blackstone life sciences.
Blackstone Life Sciences [Member]
Headquartered in state
Entity Address, State or Province
Entity Address, State or Province
Non-vested, Beginning Balance
Non-vested, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Conversion of redeemable convertible preferred stock and warrants to common stock in connection with initial public offering
Stock Issued During Period, Value, Conversion of Convertible Securities
Minimum term of royalties receivable based on annual net sales
Minimum Term Of Royalties Receivable Based On Annual Net Sales
Minimum term of royalties receivable based on annual net sales.
Initial licensing payment in escrow
Initial Licensing Payment in escrow
Initial licensing payment in escrow.
Investment, Name [Domain]
Number of shares held
Investment Owned, Balance, Shares
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, outstanding
Preferred stock shares outstanding
Preferred Stock, Shares Outstanding
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Research and Development
Research and Development Expense, Policy [Policy Text Block]
Reserved common stock
Common Stock, Capital Shares Reserved for Future Issuance
Number of target programs
Number Of Target Programs
Number of target programs.
Series D Two Redeemable Convertible Preferred Stock
Series D Two Redeemable Convertible Preferred Stock [Member]
Series D-2 redeemable convertible preferred stock.
Class of Warrant or Right
Class of Warrant or Right [Domain]
Geographical
Geographical [Axis]
Stock transaction associated with taxes withheld on restricted stock units,Shares
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Marketable Securities, Current, Total
Marketable securities
Marketable Securities, Current
Bristol-Myers Squibb Company ("BMS")
Bristol Myers Squibb Company B M S [Member]
Bristol-Myers Squibb Company ("BMS").
Laboratory Equipment
Laboratory Equipment [Member]
Laboratory equipment.
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
State tax, net of federal benefit
Schedule of Stock-Based Compensation Expense Recognized
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Other
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Exercise of common stock options
Stock Issued During Period, Value, Stock Options Exercised
Accrued Expenses and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Schedule of Components of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Upfront payment revenue recognized
Upfront Payment Revenue Recognized
Upfront payment revenue recognized.
Astellas Agreement and CFE Supply Agreement [Member]
Astellas Agreement and CFE Supply Agreement.
Astellas Agreement and CFE Supply Agreement
Non-cash interest expense on deferred royalty obligation
Non cash interest expense on deferred royalty obligation.
Non Cash Interest Expense On Deferred Royalty Obligation
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Line Items]
Share based compensation arrangement by share based payment award fair value assumptions and methodology.
March and September 2025 Restructuring Plan [Member]
March and September 2025 Restructuring Plan.
March and September 2025 Restructuring Plan
Collaboration and License Agreements and Supply Agreements
Collaboration And License Agreements And Supply Agreements [Text Block]
Collaboration and license agreements and supply agreements.
Subsequent Event
Subsequent Event [Member]
Property, Plant and Equipment [Abstract]
Research and development credits
Deferred Tax Assets, Tax Credit Carryforwards, Research
Other Assets, Noncurrent, Total
Other non-current assets
Other Assets, Noncurrent
Contract termination and other restructuring costs
Gain (Loss) on Contract Termination
Contract termination and other restructuring costs
Collaboration Agreements And Supply Agreements [Abstract]
Collaboration agreements and supply agreements.
Antidilutive Securities
Antidilutive Securities [Axis]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')
Merck K Ga A Darmstadt Germany [Member]
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name “EMD Serono”).
State
State and Local Jurisdiction [Member]
Related Party Transaction
Related Party Transaction [Axis]
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss)
Extended research term
Extended Research Term
Extended research term.
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Purchases of equipment and leasehold improvements
Payments To Acquire Equipment And Leasehold Improvements
Payments to acquire equipment and leasehold improvements.
Silicon Valley Bank
Silicon Valley Bank [Member]
Silicon Valley Bank.
Cash and Cash Equivalents
Cash and Cash Equivalents [Domain]
Milestone payment receivable upon initiation of IND enabling toxicology study
Milestone payment receivable upon initiation of IND enabling toxicology study.
Total accrued expenses and other current liabilities
Accrued expenses and other current liabilities
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities.
Preferred Stock, Value, Issued
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Total
Preferred stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2025 and December 31,2024; no shares issued and outstanding as of December 31, 2025 and December 31,2024
Proceeds from sale of future royalties net of issuance costs.
Proceeds From Sale of Future Royalties Net of Issuance Costs
Proceeds from the sale of future royalties, net of issuance costs
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Accrued Liabilities and Other Liabilities Disclosure, Current [Table Text Block]
Schedule of accrued liabilities and other liabilities disclosure, current.
Stockholders equity.
Stockholders Equity [Line Items]
Stockholders Equity [Line Items]
Minimum
Minimum
Minimum [Member]
Remeasurement of operating lease right-of-use assets for lease modification
Remeasurement of Operating Lease Right-of-Use Assets for Lease Modification
Remeasurement of operating lease right-of-use assets for lease modification
Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Financial Instrument
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Conversion of warrants to purchase of shares of common stock
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Level 3
Fair Value, Inputs, Level 3 [Member]
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Summary of significant accounting policies.
Segment Reporting [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
2018 Equity Incentive Plan
Two Thousand Eighteen Equity Incentive Plan [Member]
Two thousand eighteen equity incentive plan.
Current liabilities:
Liabilities, Current [Abstract]
Financing Component on Unearned Revenue
Financing component on unearned revenue.
Restructuring and Related Costs
Restructuring and Related Activities Disclosure [Text Block]
Return and retirement of common stocks
Stock Repurchased and Retired During Period, Value
Non-cash interest expense associated with the sale of future Vaxcyte royalties
Non cash interest expense associated with the sale of future royalties
Non Cash Interest Expense Associated With The Sale of Future Royalties
Common Stock Awards Issued and Outstanding
Common Stock Awards Issued And Outstanding [Member]
Common stock awards issued and outstanding.
Amendment Number Three Two Thousand Fifteen License Agreement.
Amendment Number Three Two Thousand Fifteen License Agreement [Member]
Amendment 3 2015 License Agreement
Common Stock Balance, Shares
Common Stock Balance, Shares
Shares, Outstanding
Marketable Securities
Marketable Securities [Member]
Marketable securities.
Operating Loss Carryforwards, Total
Net operating loss carryforwards
Operating Loss Carryforwards
Accounts receivable
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts Receivable, after Allowance for Credit Loss, Current
Lease renewal term
Lessee, Operating Lease, Renewal Term
Common Stock Warrant
Common Stock Warrant [Member]
Common Stock Warrant [Member]
Proceeds from employee stock purchase plan
Proceeds from Stock Plans
Commitments and Contingencies
Commitments and contingencies (Note 7)
Leases
Lessee, Leases [Policy Text Block]
Non-vested, Beginning balance
Non-vested, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Organization consolidation and presentation of financial statements line items.
General and Administrative Expense
General and Administrative Expense [Member]
Operating lease liabilities
Operating Lease, Liability
Auditor Firm ID
Scenario Forecast
Forecast [Member]
Marketable Securities, Noncurrent, Total
Marketable securities, non-current
Long-term marketable securities
Marketable Securities, Noncurrent
Asset Held for Sale [Policy Text Block]
Asset Held for Sale.
Asset Held for Sale
Maximum potential payments related to development regulatory commercialization contingent payments and milestones
Maximum Potential Payments Related To Development Regulatory Commercialization Contingent Payments And Milestones
Maximum potential payments related to development regulatory commercialization contingent payments and milestones.
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Deferred royalty obligation.
Deferred Royalty Obligation [Table]
Summary of Severance and Other Termination Benefit Expense and Reconciliation of Such Liability
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
Purchase of property and equipment included in accounts payable
Capital Expenditures Incurred but Not yet Paid
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Lease Contractual Term
Lease Contractual Term [Domain]
Tax and related expenses
Accrued Income Taxes, Current
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount
Stock compensation
Number of Installments
Number of installments
Number of installments.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Loss Contingencies [Table]
Loss Contingencies [Table]
Weighted-average shares used in computing basic loss per share
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted-average shares used in computing basic net loss per share
Scenario [Axis]
Warrants to Purchase Common Stock
Warrants To Purchase Common Stock [Member]
Warrants to purchase common stock.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Stock options exercisable, Aggregate Intrinsic Value, Exercisable
Estimated service period
Estimated Service Period
Estimated service period.
Exercise of common stock options and common stock warrants for cash, Shares
Stock Issued During Period Shares Stock Options And Warrants Exercised
Stock issued during period shares stock options and warrants exercised.
Stock compensation
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent
Basis of Presentation and Use of Estimates
Basis Of Presentation And Use Of Estimates Policy Policy [Text Block]
Basis of presentation and use of estimates.
Schedule of Effective Tax Rate of Provision (Benefit) for Income Taxes
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Segments [Axis]
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Domain]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cash Equivalents Unrealized Gains
Cash equivalents unrealized gains.
Less amounts classified as cash equivalents, Unrealized Gains
Deferred tax assets:
Deferred Tax Assets, Net [Abstract]
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total
Tax credits
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Tax credits
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Potential financial benefit base rent abatement
Potential Financial Benefit Base Rent Abatement
Potential financial benefit base rent abatement.
Accrued expenses and other liabilities
Increase (Decrease) in Accrued Expenses and Other Liabilities
Increase (decrease) in accrued expenses and other liabilities.
Deferred Tax Asset, In-Process Research and Development
Capitalized research and development expenditure
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Change in valuation allowance
Stockholders equity
Balances
Balances
Equity, Attributable to Parent
Total stockholders' equity (deficit)
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Sublease Agreement
Sublease Agreement [Member]
Sublease agreement.
Vaxcyte.
Vaxcyte [Member]
Vaxcyte
Statement of Stockholders' Equity [Abstract]
Series C Redeemable Convertible Preferred Stock
Series C Preferred Stock [Member]
Issuance of common stock in connection with the underwritten offering, net of issuance costs
Stock Issued During Period Value Through The Underwritten Offerings
Stock issued during period value through the underwritten offerings.
Type of Restructuring [Domain]
Cash Equivalents
Cash Equivalents [Member]
Additional milestone payment
Additional Milestone Payment
Additional milestone payment.
Over-Allotment Option [Member]
Underwritten Offering
Leasehold Improvements
Leasehold Improvements [Member]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Contracts Variable Consideration
Contracts variable consideration.
Constrained variable consideration
Adjustments and Reconciling Items
Adjustments and reconciling items.
Adjustments and reconciling items
Number Of Goods And Services
Number of goods and services.
Number of goods and services
Non-cash fair value equity securities
Value of 167,780 shares of Vaxcyte common stock received under the Vaxcyte Agreement
Investment Owned, at Fair Value, Ending Balance
Investment Owned, at Fair Value, Beginning Balance
Investment Owned, Fair Value
Additions / (Reductions) for tax positions of prior years
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
Unrecognized tax benefits increase (decrease) resulting from prior period tax positions.
Date of incorporation
Entity Incorporation, Date of Incorporation
Supplemental Disclosures of Non-cash Investing and Financing Information
Noncash Investing and Financing Items [Abstract]
Vaxcyte agreements.
Vaxcyte Agreements [Member]
Vaxcyte Agreements
Five Prime Therapeutics, Inc. (the “Sublessor”)
Five Prime Therapeutics Inc [Member]
Five Prime Therapeutics, Inc.
Severance and Change in Control Plan [Member]
Severance and change in control plan.
CIC Plan
Schedule of Reconciliation of Unrecognized Tax Benefits
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Plan Name
Plan Name [Domain]
Eliminations And Reconciling Items [Member]
Eliminations and reconciling items.
Adjustments and Reconciling Items
Cumulative adjustment to revenue
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price
Schedule of Fair Value of ESPP Shares Using Option Pricing Model
Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]
Withholding tax on deferred revenue.
Withholding Tax On Deferred Revenue
Withholding tax on deferred revenue
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Schedule of Common Stock Reserved for Future Issuance
Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]
Schedule of common stock reserved for future issuance.
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Note Receivable from Stockholder
Receivables from Stockholder [Member]
Ipsen Pharma S A S [Member]
Ipsen Pharma S A S.
Ipsen Pharma SAS
Impairment, Long-Lived Asset, Held-for-Use
Impairment, Long-Lived Asset, Held-for-Use, Total
Losses on assets held for sale
Loss on assets held for sales
State
Current State and Local Tax Expense (Benefit)
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Income tax disclosure.
Income Tax Disclosure [Table]
Income Tax Disclosure [Table]
Deferred Charges, Policy [Policy Text Block]
Deferred Royalty Obligation related to the Sale of Future Royalties and Non-cash Interest Expense
Restructuring Plan [Axis]
Related Party
Related and Nonrelated Parties [Axis]
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Other
Property and Equipment, Net
Property, Plant and Equipment, Policy [Policy Text Block]
Leerink Partners LLC and TD Securities (USA) LLC
Leerink Partners LLC and TD Securities (USA) LLC [Member]
Leerink partners LLC and td securities (USA) LLC.
Accounting Standards Update Extensible List
Accounting Standards Update [Extensible Enumeration]
Area of Sublease Premises
Area of Real Estate Property
Headquartered in
Entity Address, City or Town
Entity Address, City or Town
Cash, Cash Equivalents, Marketable Securities and Restricted Cash
Cash Cash Equivalents Marketable Securities And Restricted Cash Policy [Text Block]
Cash, cash equivalents, marketable securities and restricted cash.
Security Exchange Name
Security Exchange Name
March 2025 Restructuring Plan [Member]
March 2025 Restructuring Plan.
March 2025 Restructuring Plan
Other
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Property, Plant and Equipment, Gross, Ending Balance
Property, Plant and Equipment, Gross, Beginning Balance
Property, Plant and Equipment, Gross, Total
Total
Property, Plant and Equipment, Gross
Additional Payment Related To Sales Milestone
Additional payment related to sales milestone.
Payments related to sales milestone
Counterparty Name
Counterparty Name [Axis]
Loss before provision for income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Shares available for grant, increase
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Increase
Share based compensation arrangement by share based payment award number of shares available for grant , increase.
Percentage of interest rate amortize liability
Percentage of interest rate amortize liability
Percentage Of Interest Rate Amortize Liability
First Cytokine-Derivative Program
First Cytokine Derivative Program [Member]
First cytokine-derivative program.
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Stockholders' Equity Note [Abstract]
Transaction costs incurred.
Transaction costs incurred
Transaction costs incurred
Total cash, cash equivalents and restricted cash shown in the Statements of Cash Flows
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash paid for interest
Interest Paid, Excluding Capitalized Interest, Operating Activity
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statistical Measurement
Statistical Measurement [Domain]
Exercise price per share
Exercise price per share
Class of Warrant or Right, Exercise Price of Warrants or Rights
Total current assets
Assets, Current
Total stock-based compensation expense
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Vaxcyte Common Stock
Vaxcyte Common Stock [Member]
Vaxcyte common stock.
Document Period End Date
Document Period End Date
Number of performance obligations
Number Of Performance Obligations
Number of performance obligations.
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Defined Contribution Plan, Cost
Contribution expenses
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Revenue recognition aggregate contingent payments eligible to receive
Revenue Recognition Aggregate Contingent Payments Eligible To Receive
Revenue recognition aggregate contingent payments eligible to receive.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Stock options exercisable, Shares
Statement of Financial Position [Abstract]
Restricted Stock Units
Restricted Stock Units (RSUs) [Member]
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Cumulative Effect Period of Adoption Adjustment
Adoption of Accounting Standards Update (ASU) 2014-09
Cumulative Effect, Period of Adoption, Adjustment [Member]
Revenue Recognition
Revenue [Policy Text Block]
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock [Member]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Class of Stock
Class of Stock [Axis]
Loan and Security Agreement
Loan And Security Agreement [Member]
Loan and security agreement.
Deferred Tax Liabilities, Net, Total
Total deferred tax liabilities
Deferred Tax Liabilities, Net
Total current provision for income taxes
Current Income Tax Expense (Benefit)
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Deferred tax assets operating lease liability.
Deferred Tax Assets Operating Lease Liability
Operating lease liability
Total liabilities
Liabilities
Financial Instruments
Financial Instruments [Domain]
Accrued restructuring-related cost
Restructuring and Related Cost, Incurred Cost
Financing component associated with program fees
Financing Component Associated with Program Fees
Financing component associated with program fees.
Collaboration and license agreements and supply agreement accruals
Collaboration and License Agreements and Supply Agreement Accruals Current
Collaboration and license agreements and supply agreement accruals current.
September Twenty Twenty Five Restructuring Plan [Member]
September twenty twenty five restructuring plan.
September 2025 Restructuring Plan
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total
Accruals and other
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
Period from issuance date of unaudited interim condensed financial statements
Period From Issuance Of Unaudited Interim Condensed Financial Statements
Period from issuance of unaudited interim condensed financial statements
Shares Reserved for Issuance Under 2018 Employee Stock Purchase Plan
2018 Employee Stock Purchase Plan
Two Thousand Eighteen Employee Stock Purchase Plan [Member]
Two thousand eighteen employee stock purchase plan.
Schedule Of Cash And Cash Equivalents [Table]
Cash and Cash Equivalent [Table]
Weighted-average shares used in computing diluted loss per share
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted-average shares used in computing diluted net loss per share
Offering costs included in accounts payable
Offering Costs Included In Accounts Payable
Offering costs included in accounts payable.
Entity File Number
Securities Act File Number
Cumulative change in ownership percentage
Cumulative Change In Ownership Percentage
Cumulative change in ownership percentage.
Cover
Cover [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Expected volatility, Minimum
Investment Income, Nonoperating, Total
Interest income
Investment Income, Nonoperating
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Axis]
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Scenario [Domain]
Upfront license fee
Upfront License Fee
Upfront license fee.
Maximum number of shares issuable
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of operating segments
Number of Operating Segments
Sale of Stock
Sale of Stock [Domain]
Reimbursements expenses accruals
Reimbursements Expenses Accruals
Reimbursements expenses accruals.
Deferred rent
Deferred Rent Credit, Noncurrent
BofA Securities, Inc.
BofA Securities, Inc
BofA Securities, Inc [Member]
Segment Reporting
Segment Reporting Disclosure [Text Block]
General and Administrative Expense, Total
General and administrative
General and Administrative Expense
Reduction of research and development expenses recognized
Reduction of Research and Development Expenses Recognized
Reduction of research and development expenses recognized.
Revenue recognized from contingent payment
Revenue recognized from contingent payment , net of withholding tax.
Revenue Recognized From Contingent Payment , Net Of Withholding Tax
Collaboration and License Agreements and Supply Agreements
Collaboration And License Agreements And Supply Agreements [Member]
Collaboration and license agreements and supply agreements.
Less amounts classified as cash equivalents, Unrealized Losses
Cash Equivalents Unrealized Losses
Cash equivalents unrealized losses.
Conversion of redeemable convertible preferred stock warrants to common stock warrants in connection with initial public offering
Adjustments to Additional Paid in Capital, Warrant Issued
Operating lease expense
Operating Lease, Expense
Shares
Shares received
Stock Received During Period Shares
Stock received during period shares.
Restructuring Charges
Expense recognized during the period
Restructuring Charges, Total
Expenses amounted
Property and equipment useful lives
Property, Plant and Equipment, Useful Life
Recent Accounting Pronouncements Not Yet Adopted
New Accounting Pronouncements, Policy [Policy Text Block]
Schedule of Maturities of Operating Lease Liabilities
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Deferred revenue-current
Contract with Customer, Liability, Current
Deferred royalty obligation.
Deferred Royalty Obligation [Line Items]
Deferred tax assets deferred royalty obligation.
Deferred Tax Assets Deferred Royalty Obligation
Deferred royalty obligation
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering, shares
Stock Issued During Period, Shares, Conversion of Convertible Securities
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Other
Shares vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Employee Severance [Member]
Employee Severance
Contingent payment.
Contingent Payment [Member]
Contingent Payment
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate
Maximum Amount Eligible To Receive For Development Regulatory And Commercial Milestones For Each Product Candidate
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate.
Risk-free interest rate, Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Income (Loss) from Continuing Operations before Income Taxes, Domestic
United States
Amount
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Fair Market Value of Common Stock Issued
Fair market value of common stock issued.
Fair market value of common stock issued
Investment, Type [Extensible Enumeration]
Unrecognized stock-based compensation expense
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Nonrefundable, non-creditable upfront payment receivable
Nonrefundable Noncreditable Upfront Payment Receivable
Nonrefundable non-creditable upfront payment receivable.
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total
Interest and penalties incurred
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
San Carlos Lease
San Carlos Lease [Member]
San carlos lease.
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Operating lease liability - current
Less: current portion
Operating lease liabilities current
Operating Lease, Liability, Current
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Depreciation and amortization
Depreciation and amortization expense
Depreciation, Depletion and Amortization, Total
Depreciation, Depletion and Amortization
Revenue, remaining performance obligation, amount
Revenue, Remaining Performance Obligation, Amount
Cybersecurity Risk Management Processes Integrated [Flag]
Document Transition Report
Document Transition Report
Facility and maintenance expenses
Facility and maintenance expenses.
Facility and maintenance expenses
Facility and maintenance expenses
Deferred Tax Assets, Net
Total net deferred tax assets
Payment received from definitive agreement.
Payment Received From Definitive Agreement
Payment received from definitive agreement
Total operating expenses
Operating Expenses
Operating expenses
Limitations in use of net operating losses
Operating Loss Carryforwards, Limitations on Use
Research and Development Expense, Total
Research and development
Research and Development Expense
Asset Impairment Charges
Asset Impairment Charges, Total
Asset impairment charges
Impairment charges
Leasehold impairment charges
Deferred royalty obligation.
Deferred Royalty Obligation [Abstract]
Return and retirement of common stock
Return and retirement of common stock
Payments for Repurchase of Common Stock
Schedule of Current Provision for Income Taxes
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Conversion of redeemable convertible preferred stock and warrant to common stock in connection with initial public offering, Shares
Temporary Equity Conversion Of Redeemable Convertible Preferred Stock And Warrant To Common Stock Shares
Temporary equity conversion of redeemable convertible preferred stock and warrant to common stock shares.
Statement of Cash Flows [Abstract]
EMD Serono
E M D Serono [Member]
EMD Serono.
Weighted Average Grant-Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonrefundable, non-creditable upfront payment
Nonrefundable, Non-creditable Upfront Fee Payment
Nonrefundable, non-creditable upfront fee payment.
Current Federal Tax Expense (Benefit)
Federal
Issuance of common stock in connection with initial public offering, net of issuance costs
Stock Issued During Period, Value, New Issues
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement
Summary of Option Activity
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Assets:
Assets, Fair Value Disclosure [Abstract]
Other Than Temporary Impairment Losses Debt Securities Available For Sale Recognized In Earnings
Other than temporary impairment losses debt securities available for sale recognized in earnings.
Recognition of other-than-temporary impairment
Stockholders' Equity
Equity [Text Block]
Net Loss Per Share
Earnings Per Share [Text Block]
Unrecognized tax benefits if recognized that would impact effective tax rate
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Summary of Status and Activity of Non-vested RSUs
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Other
Deferred Tax Liabilities, Other
Cybersecurity Risk Management Processes Integrated [Text Block]
Net (loss) income
Net loss
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Stock options outstanding, Aggregate Intrinsic Value, Balance
Issuance of Series C and E redeemable convertible preferred stock, net of issuance costs, Shares
Temporary Equity Stock Issued During Period Shares New Issues
Temporary equity stock issued during period shares new issues.
Operating lease cost
Operating Lease, Cost
Business Segment
Business segment [Member]
Business segment [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss), Total
Unrealized gain (loss) on equity securities
Equity Securities, FV-NI, Unrealized Gain (Loss)
Unrealized gain on equity securities
Unrealized gain on equity securities
Expected dividend yield
Expected dividend
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Operating lease payments
Operating Lease, Payments
Assets
Assets [Abstract]
MDA Agreement
M D A Agreement [Member]
MDA agreement.
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Construction in Progress
Construction in Progress [Member]
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Payments of debt
Repayments of Debt
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Revenue, remaining performance obligation, expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Retirement Benefits [Abstract]
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Schedule of Components of Loss Before Income Tax Provision
Research and Development Expense
Research and Development Expense [Member]
Number of programs advancing through preclinical development
Number Of Programs Advancing Throughout Preclinical Development
Number of programs advancing throughout preclinical development.
Warrants issued to lenders
Warrants Issued To Lenders
Warrants issued to lenders.
Research and Development Expenses
Research Tax Credit Carryforward [Member]
Restructuring Cost and Reserve [Line Items]
Fair Value Measurements
Fair Value Measurement, Policy [Policy Text Block]
Asset, Held-for-Sale, Not Part of Disposal Group
Asset, Held-for-Sale, Not Part of Disposal Group, Total
Assets as held-for-sale assets
Exercise of common stock options and common stock warrants for cash
Stock Issued During Period Value Stock Options And Warrants Exercised
Stock issued during period value stock options and warrants exercised.
Proceeds from Stock Options Exercised
Proceeds from exercise of common stock options
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total
Tax credits
Tax credits
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Royality Issuance costs.
Royality Issuance costs
Issuance costs
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]
Tasly License Agreement
Tasly License Agreement [Member]
Tasly license agreement.
Share-Based Payment Arrangement [Abstract]
Total unrecognized compensation cost related to unvested granted
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Materials Supply
Materials supply.
Materials supply
Upfront payment withholding tax amount
Upfront Payment Withholding Tax Amount
Upfront payment withholding tax amount.
Assets, Fair Value Disclosure, Total
Securities held
Total
Assets, Fair Value Disclosure
Equipment and office related expenses
Equipment and office related expenses.
Equipment and office-related expenses
Equipment and office-related expenses
Issuance of Series C and E redeemable convertible preferred stock, net of issuance costs
Temporary Equity, Stock Issued During Period, Value, New Issues
Sale of Stock [Axis]
Sale of Stock
Collaboration And License Agreements And Supply Agreements [Abstract]
Collaboration and license agreements and supply agreements.
Revenues, Total
Total revenue
Revenues
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Deferred tax liabilities:
Deferred Tax Liabilities, Net [Abstract]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted - Average Exercise Price, Canceled and forfeited
Canceled
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Money Market Funds
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Issuance of common stock in connection with private placement, Shares
Stock Issued During Period Shares With Private Placement
Stock issued during period share with private placement.
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Industrial Lease
Industrial Lease [Member]
Industrial lease.
Other non-current liabilities
Other Liabilities, Noncurrent, Total
Other Liabilities, Noncurrent
Restructuring Plan [Domain]
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Summary of Property and Equipment, Net
Property, Plant and Equipment [Table Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Stock options outstanding, Weighted - Average Exercise Price, Beginning Balance
Stock options outstanding, Weighted - Average Exercise Price, Ending Balance
Income Tax Disclosure [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Gross unrecognized tax benefit beginning balance
Gross unrecognized tax benefit ending balance
Unrecognized Tax Benefits
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Stock Issued During Period Shares Through The Underwritten Offering
Stock issued during period shares through the underwritten offering.
Issuance of common stock in connection with the underwritten offering, net of issuance costs , Shares
Recognition of up front payment
Revenue Recognition Of Up Front Payment Amount
Revenue recognition of up-front payment amount.
Measurement Frequency
Measurement Frequency [Domain]
Income Statement Location
Statement of Income Location, Balance [Axis]
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Property and Equipment, Net
Property, Plant and Equipment Disclosure [Text Block]
Estimated fair value of equity securities
Investment in equity securities
Equity Securities, FV-NI, Current
Risk-free interest rate, Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Summary of Recognized Revenue
Milestone Method Revenue Recognition Table [Text Block]
Milestone method revenue recognition.
Subsequent Event Type [Axis]
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Supply Agreement
Supply Agreement [Member]
Supply agreement.
Fair Value Measurements Recurring
Fair Value, Recurring [Member]
Total lease payments
Aggregate estimated base rent payments due
Lessee, Operating Lease, Liability, to be Paid
Less: imputed interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Unrestricted cash, cash equivalents and marketable securities
Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
Unrestricted cash, cash equivalents and marketable securities at carrying value.
San Carlos Lease And Industrial Lease [Member]
San carlos lease and industrial lease.
San Carlos Lease and Industrial Lease
Premium On Common Stock Issued
Premium on common stock issued,
Premium on common stock issued to Ipsen Biopharma, Inc. (USA)
Exercise of preferred stock warrants for cash, Shares
Stock Issued During Period Value Preferred Stock Warrants Exercised
Stock issued during period value preferred stock warrants exercised.
Equity Components
Equity Components [Axis]
Issuance of common stock in connection with At-The-Market sale, net of issuance costs
Stock Issued During Period Value Through At The Market Sale
Stock issued during period value through At The Market sale.
BioNova Pharmaceuticals, Ltd. ("BioNova")
BioNova Pharmaceuticals, Ltd. (BioNova) [Member]
Bionova pharmaceuticals, ltd. (bionova).
Non-operating income
Nonoperating Income (Expense)
Equity Component
Equity Component [Domain]
Asset Class
Asset Class [Axis]
Restructuring Policy [TextBlock]
Restructuring.
Restructuring
Deferred revenue
Deferred Tax Assets, Deferred Income
Document Annual Report
Document Annual Report
Deferred royalty obligation related to the sale of future royalties, classified as noncurrent.
Deferred Royalty Obligation Related To Sale Of Future Royalties, Noncurrent
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net
Deferred royalty obligation related to the sale of future royalties
Proceeds from Income Tax Refunds
Income tax refunds
Vesting of restricted stock units, Shares
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
IPO
IPO [Member]
Issuance of common stock under Employee Stock Purchase Plan, Shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]
Voting rights per share
Common Stock, Voting Rights
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total
Changes in unrecognized tax benefits
Statement of Comprehensive Income [Abstract]
Future Services on Collaboration Joint Steering Committee ("JSC")
Future Services On Collaboration Joint Steering Committee [Member]
Future services on collaboration Joint Steering Committee.
Maximum
Maximum
Maximum [Member]
Stock Issued During Period Shares Through At The Market Sale
Issuance of common stock in connection with At-The-Market sale, net of issuance costs, Shares
Stock issued during period shares through At The Market sale.
Statistical Measurement
Statistical Measurement [Axis]
Weighted - Average Exercise Price, Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Deferred revenue, non-current
Contract with Customer, Liability, Noncurrent
Tax credit carryforward expiration year
Tax Credit Carryforward Expiration Year
Tax credit carryforward, expiration year.
Common stock fair value
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued
Common Stock, value, issued
Common stock, $0.001 par value - 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 8,584,309 and 8,306,398 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively
Ongoing Performance Related to Unsatisfied Performance Obligations
Ongoing Performance Related To Unsatisfied Performance Obligations [Member]
Ongoing performance related to unsatisfied performance obligations.
2018 BMS Master Services Agreement
Two Thousand Eighteen BMS Master Services Agreement [Member]
Two thousand eighteen BMS master services agreement.
Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year
Increase In Stock Reserved For Issuance As Percentage Of Capital Stock Outstanding On Last Day Of Preceding Year
Increase in stock reserved for issuance as percentage of capital stock outstanding on last day of preceding year.
Cash and Cash Equivalents [Abstract]
Warrant exercised
Warrants and Rights Outstanding
Royalty Member
Royalty [Member]
Royalty
Deferred Tax Assets, Operating Loss Carryforwards, Total
Net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Tax Credit Carryforward
Tax Credit Carryforward [Axis]
ESPP
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
2018 Employee Stock Purchase Plan.
Impairment of Long-Lived Assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Cash And Cash Equivalents [Line Items]
Cash and Cash Equivalents [Line Items]
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State tax, net of federal benefit
Entity Public Float
Entity Public Float
Expected volatility
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Preferred stock shares authorized
Preferred stock shares authorized
Preferred Stock, Shares Authorized
Taxes paid related to net share settlement of restricted stock units
Payment, Tax Withholding, Share-Based Payment Arrangement
Investments in an unrealized loss position
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss, Total
Schedule of Cash Equivalents and Marketable Securities
Cash, Cash Equivalent, and Investment [Table Text Block]
ATM
Atthe Market Issuance Sales Agreement
At-the-Market (“ATM")
At-the-Market issuance sales agreement.
Entity Registrant Name
Entity Registrant Name
Additions to deferred revenue
Contract With Customer Liability Additions
Contract with customer liability additions.
Travel related expenses
Travel related expenses.
Travel-related expenses
Travel-related expenses
Unrealized Losses
Unrealized losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Entity Voluntary Filers
Entity Voluntary Filers
Recognition of revenue
Recognition of revenue in current period
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Provision for income taxes
Income Tax Expense (Benefit)
Total
Income tax expense
Income tax (benefit) expense
Measurement Frequency
Measurement Frequency [Axis]
Lease extension period
Lessee Operating Lease Option To Extend Period
Lessee operating lease option to extend period.
Net proceeds from issuance of common stock
Proceeds from sales of common stock to Ipsen Biopharmaceuticals, Inc. (USA)
Proceeds from issuance of common stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payment related to development and regulatory milestone
Additional Payment Related To Development And Regulatory Milestone
Additional payment related to development and regulatory milestone.
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Restructuring Impairment And Other Costs Of Deprioritized Program [Member]
Restructuring impairment and other costs of deprioritized program..
Restructuring, and Related Costs
Concentrations of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Initial licensing payment due
Initial Licensing Payment due
Initial licensing payment due.
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive income
Consolidation Items [Axis]
Payments for Restructuring
Payments during the period
Payments incurred during the period
Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Restrictions on Cash and Cash Equivalents [Table Text Block]
Gain (Loss), Foreign Currency Transaction, after Tax
Gain (Loss), Foreign Currency Transaction, after Tax, Total
Foreign currency transaction loss
Total assets
Assets
Schedule Of Property Plant And Equipment [Table]
Property, Plant and Equipment [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Stock options exercisable, Weighted - Average Remaining Contract Term, Exercisable
Income Statement [Abstract]
Restructuring Cost [Table]
Expansion Premises
Expansion Premises [Member]
Expansion premises.
Marketable securities maturity period
Marketable Securities Maturity Period
Marketable securities maturity period.
Milestone method revenue recognition description
Milestone Method Revenue Recognition Description
Milestone method revenue recognition description.
Stock-Based Compensation
Share-Based Payment Arrangement [Policy Text Block]
Cash Equivalents and Marketable Securities
Cash, Cash Equivalent, and Marketable Security [Text Block]
Realized gain on sale of equity securities
Realized gain (loss) on equity securities
Realized gain on sale of equity securities
Equity Securities, FV-NI, Realized Gain (Loss)
Equity Securities, FV-NI, Realized Gain (Loss), Total
Research and Development Services
Research and Development Services
Research and development services.
Issuance of common stock in connection with public offering, net of issuance costs, Shares
Shares of common stock
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement, Shares
Released
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Net loss per share, diluted
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Summary of Segment Net Loss Including Significant Segment Expenses
Operating Segment
Operating Segments [Member]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Percent
Preferred stock, conversion basis
Preferred Stock, Conversion Basis
City Area Code
City Area Code
Oxford Finance LLC
Oxford Finance Limited Liability Company [Member]
Oxford Finance Limited Liability Company.
Auditor Name
Maximum refund period on termination of study.
Maximum Refund Period On Termination Of Study
Maximum refund period on termination of study
Upfront payment revenue not yet recognized.
Upfront Payment Revenue Not Yet Recognized
Upfront payment revenue not recognized
Operating Leases, Rent Expense, Net, Total
Rent expense
Operating Leases, Rent Expense, Net
Supranational Debt Securities
Supranational Debt Securities [Member]
Supranational Debt Securities.
Counterparty Name
Counterparty Name [Domain]
Clinical trial expense and other third-party costs for the deprioritization of the luvelta program
Business Exit Costs
Operating loss carryforwards expiration year
Operating Loss Carryforwards Expiration Year
Operating loss carryforwards expiration year.
Variable lease cost
Variable Lease, Cost
Issuance of common stock under Employee Stock Purchase Plan
Stock Issued During Period, Value, Employee Stock Purchase Plan
Deferred rent
Increase (Decrease) in Deferred Charges
Operating lease, weighted average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Segment Reporting Information [Line Items]
Reverse stock split
Stockholders' Equity Note, Stock Split, Conversion Ratio
Lease expiration Date
Lease Expiration Date
Total lease cost
Lease, Cost
Laboratory supplies
Laboratory supplies.
Laboratory supplies
Laboratory supplies
August 2017 Loan
August Two Thousand Seventeen Loan [Member]
August two thousand seventeen loan.
Merck Sharp & Dohme Corp
Merck Sharp & Dohme Corporation ("Merck")
Merck Sharp And Dohme Corporation [Member]
Merck Sharp and Dohme Corporation.
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Total property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net
Deferred tax liabilities operating lease right of use asset.
Deferred Tax Liabilities Operating Lease Right Of Use Asset
Operating lease right-of-use asset
Operating lease right-of-use asset
Vesting of restricted stock units
Vesting of restricted stock units
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
Common Stock, Premium Value
Common stock premium value.
Common stock premium
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Loss from operations
Operating Income (Loss)
Debt-current
Debt, Current, Total
Debt, Current
Accumulated Deficit
Retained Earnings [Member]
Noncash Lease Expenses
Noncash lease expenses
Non-cash lease expenses
Cash and Cash Equivalents
Cash and Cash Equivalents [Axis]
Share-based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Schedule of Future Minimum Payments under Noncancelable Operating Leases and Sublease
Lessee Operating Leases And Sublease Liability Maturity Table [Text Block]
Lessee operating leases and sublease liability maturity.
Restricted Stock Units Issued and Outstanding
Restricted Stock Units Issued And Outstanding [Member]
Restricted stock units issued and outstanding.
Liability Related Sale Of Future Vaxcyte Royalties
Liability Related Sale Of Future Vaxcyte Royalties
Liability related to the sale of future Vaxcyte royalties - ending balance
Liability related to sale of future Vaxcyte royalties - beginning balance
CMO.
CMO [Member]
CMO
Aggregate Transaction Price
Aggregate transaction price.
Total transaction price
Operating lease, weighted average discount rate, percent
Operating Lease, Weighted Average Discount Rate, Percent
Total lease liabilities, non-current
Operating lease liability - non-current
Operating Lease, Liability, Noncurrent
Level 1
Fair Value, Inputs, Level 1 [Member]
Disclosure Text Block [Abstract]
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Schedule of Components of Lease Costs
Lease, Cost [Table Text Block]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Auditor Location
Lease base rent abatement
Lessee Operating Lease Liability Of Base Rent Abatement Amount
Lessee operating lease liability of base rent abatement amount.
Outside services
Outside services.
Outside services
Outside services
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Table]
Share based compensation arrangement by share based payment award fair value assumptions and methodology.
Income Tax Disclosure [Line Items]
Income Tax Disclosure [Line Items]
Income tax disclosure.
U.S. Government Securities
US Government Corporations and Agencies Securities [Member]
Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Corporate Debt Securities
Corporate Debt Securities [Member]
Income Tax Authority
Income Tax Jurisdiction [Domain]
Entity Interactive Data Current
Entity Interactive Data Current
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Income Statement Location
Statement of Income Location, Balance [Domain]
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Oxford Finance LLC and Silicon Valley Bank
Oxford Finance Limited Liability Company And Silicon Valley Bank [Member]
Oxford finance limited liability company and silicon valley bank.
Summary of the Status of Call Options
Summary Of Status Of Call Options Table [Text Block]
Summary of status of call options.
Accretion (Amortization) of Discounts and Premiums, Investments
Accretion of discount on marketable securities
Additional milestone payment receivable.
Additional Milestone Payment Receivable
Additional milestone payment receivable
Exercise of preferred stock warrants for cash
Stock Issued During Period Value Preferred Stock Warrants Exercised Value
Stock issued during period value preferred stock warrants exercised value.
BMS Agreement
BMS Agreement [Member]
BMS agreement.
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Domain]
Entity Tax Identification Number
Entity Tax Identification Number
Amended and Restated 2021 Equity Inducement Plan
Amended And Restated Two Thousand Twenty One Equity Inducement Plan [Member]
Amended and restated two thousand twenty one equity inducement plan.
Common stock, issuance costs
Common Stock Issuance Costs
Common stock issuance costs.
Local Phone Number
Local Phone Number
Related Party Transaction
Related Party Transaction [Domain]
Shares to be issued under ESPP
Shares To Be Issued Under E S P P [Member]
Shares to be issued under ESPP.
Other
Other Liabilities, Current
Short-term lease cost
Short-Term Lease, Cost
Denominator:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Auditor Opinion [Text Block]
Auditor Opinion
Restructuring Costs
Restructuring and related costs
Total
Restructuring and related costs
Public Offerings
Public Offering
Public Offerings [Member]
Public offerings.
Accounting Policies [Abstract]
Summary of Deferred Revenue Balance
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Revenue
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Revenue
Numerator:
Net Income (Loss) Attributable to Parent [Abstract]
Nonrefundable upfront payment receivable
Nonrefundable Upfront Payment Receivable
Nonrefundable upfront payment receivable.
Reimbursements expenses
Reimbursements expenses.
Class of Stock
Class of Stock [Domain]
Commercial Paper
Commercial Paper [Member]
Labor and Related Expense
Personnel-related expenses
Personnel-related expenses
Shares available for grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Remaining unrecognized compensation cost expected to be recognized over weighted-average period
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Entity Emerging Growth Company
Entity Emerging Growth Company
Tax Credit Carryforward, Name
Tax Credit Carryforward, Name [Domain]